BAH: 10-K Risk Factor Changes

2025 vs 2024  ·  SEC EDGAR  ·  2026-05-22
Other years: 2024 vs 2023 · 2023 vs 2022
⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

Booz Allen Hamilton removed five risks from its 2025 filing, including pandemic-related exposure and Sarbanes-Oxley compliance burdens, while substantively modifying 14 existing risks - most notably those covering debt management, cybersecurity threats, and government contract dependency. The company made no net additions to its risk factor disclosure, instead consolidating and reframing existing risks to reflect current business priorities. The 43 unchanged risks indicate continuity in BAH's core risk profile, with strategic emphasis shifts toward financial leverage and security vulnerabilities rather than regulatory or pandemic concerns.

✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

0
New Risks
5
Removed
14
Modified
43
Unchanged
🔴 No Match in Current Filing

The effects of a disease outbreak, pandemic or widespread health epidemic could have a material adverse effect on our business and results of operations.

This section from the 2024 filing does not have a high-confidence textual match in the 2025 filing. It may have been removed, merged, or substantially reworded.

Disease outbreaks, pandemics or similar widespread health epidemics and attempts to contain and reduce their spread may adversely affect U.S. and global economies, including impacts to supply chains, customer demand, international trade, and capital markets. These effects may…

View 2024 text

Disease outbreaks, pandemics or similar widespread health epidemics and attempts to contain and reduce their spread may adversely affect U.S. and global economies, including impacts to supply chains, customer demand, international trade, and capital markets. These effects may adversely affect certain of our business operations and may materially and adversely affect our financial condition, results of operations, cash flows, and equity. We have taken precautionary measures intended to minimize the risk of disease outbreaks, pandemics or similar widespread health epidemics, to our employees, our clients, and the communities in which we operate, as well as remedial measures to address residual, lasting issues, including increased medical costs and a rise in mental health issues, which could negatively impact our business. In addition, some of our employees, clients, and subcontractors are located in foreign countries, which may be impacted differently from the United States depending on their circumstances. Although the Company has business continuity plans and other safeguards in place, there is no assurance that such plans and safeguards will be effective or that such measures will not adversely affect our operations or long-term plans. In addition, as local conditions and regulations respond to the risks of disease outbreaks, pandemics or similar widespread health epidemics regarding the return of employees to offices generally, our workforce may not be able to return to work in person immediately, if at all, or may instead choose to pursue competing employment opportunities, including as a result of transportation, childcare, and ongoing health issues, which could negatively affect our business. In addition, disease outbreaks, pandemics or widespread health epidemics may disrupt the operations of our clients, suppliers, vendors, service providers, and subcontractors, including as a result of travel restrictions, business shutdowns, key material shortages, or lack of access to financial markets, all of which could negatively impact our business and results of operations. Any inability to develop alternative sources of supply on a cost-effective and timely basis could materially impair our ability to provide products, systems, and services to our clients.

🔴 No Match in Current Filing Our professional reputation and relationships with U.S. government agencies are critical to our business, and any harm to our reputation or relationships could decrease the amount of business the U.S. government does with us, which could have a material adverse effect on our future revenue and growth prospects. 🔒
🔴 No Match in Current Filing The operation of financial management systems may have an adverse effect on our business and results of operations. 🔒
🔴 No Match in Current Filing Fulfilling our obligations incident to being a public company, including with respect to the requirements of and related rules under the Sarbanes Oxley Act of 2002, is expensive and time consuming and any delays or difficulty in satisfying these obligations could have a material adverse effect on our future results of operations and our stock price. 🔒
🔴 No Match in Current Filing Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our current or former directors, officers, or stockholders. 🔒
🟡 Modified We have substantial indebtedness and may incur substantial additional indebtedness, which could adversely affect our financial health and our ability to obtain financing in the future as well as to react to changes in our business. 🔒
🟡 Modified Systems that we develop, integrate, maintain, or otherwise support could experience security breaches which may damage our reputation with our customers and hinder future contract win rates. 🔒
🟡 Modified We depend on contracts with U.S. government agencies for substantially all of our revenue. If our reputation or relationships with such agencies are harmed, our future revenue and operating profits would decline. 🔒
🟡 Modified Legal and Regulatory Risks 🔒
🟡 Modified We may fail to obtain and maintain necessary security clearances which may adversely affect our ability to perform on certain contracts. 🔒
🟡 Modified We develop and utilize artificial intelligence, which could expose us to risks including potential liability as well as regulatory, competition, reputational and other risks. 🔒
🟡 Modified Global inflationary pressures and new or increased tariffs on certain imports have increased the prices of goods and services, which could raise the costs associated with providing our services, diminish our ability to compete for new contracts or task orders, and/or reduce customer buying power. 🔒
🟡 Modified Risks Related to Our Common Stock 🔒
🟡 Modified The U.S. government may prefer small and small disadvantaged businesses; therefore, we may have fewer opportunities to bid for. 🔒
🟡 Modified U.S. government spending levels and mission priorities could change in a manner that adversely affects our future revenue and limits our growth prospects. 🔒
🟡 Modified Implementation of and compliance with various data privacy and cybersecurity laws, regulations and standards could require significant investment into ongoing compliance activities, trigger potential liability, and limit our ability to use personal data. 🔒
🟡 Modified Certain services we provide and technologies we develop are designed to prevent, detect and monitor threats to our customers and may expose us or our customers and business partners to financial loss or physical or reputational harm. 🔒
🟡 Modified Increasing scrutiny and changing expectations regarding business operations and associated practices related to matters receiving substantial scrutiny from stakeholders and governmental authorities may impose additional costs on us or expose us to new or additional risks. 🔒
🟡 Modified Our business is subject to disruption caused by physical or transition risks that could adversely affect our results of operations or financial condition. 🔒
18 more changes in this filing

Full diff access, historical comparisons, and cross-company signal tracking.

Get full access — from $29/month Already a Pro subscriber? View full diff →